Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection
Open Access
- 1 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Endocrine
- Vol. 69 (2), 430-440
- https://doi.org/10.1007/s12020-020-02289-2
Abstract
Purpose Surgical resection is the only effective curative strategy for small intestinal neuroendocrine neoplasms (SINENs). Nevertheless, the evaluation of residual disease and prediction of disease recurrence/progression remains a problematic issue. Methods We evaluated 13 SINENs that underwent surgical resection of the primary tumour and/or mesenteric mass. Patients were divided in three groups: (a) Group 1: SINENs that underwent resection with curative intent, (b) Group 2: SINENs treated with resection in the setting of metastatic disease, which remained stable and (c) Group 3: SINENs treated with resection in the setting of metastatic disease, with evidence of any progression at follow-up. NETest and chromogranin A were measured pre-operatively and post-operatively during a 22-month median follow-up period and compared with imaging studies. NETest score = 80% high score. Results NETest score was raised in all (100%) SINENs pre-operatively. Surgery with curative intent resulted in NETest score reduction from 78.25 +/- 15.32 to 25.25 +/- 1.75 (p < 0.05). Low NETest scores post-operatively were evident in all cases without clinical evidence of residual disease (Group 1). However, the low disease activity score suggested the presence of microscopic residual disease. In three cases (75%) with stable disease (Group 2) the NETest score was low consistent with indolent disease. In the progressive disease group (Group 3), a high NETest score was present in three cases (60%) and an intermediate NETest score in the remainder (40%). Conclusions Blood NETest scores accurately identified SINENs and were significantly decreased by curative surgery. Monitoring NETest post-operatively may facilitate management by identifying the presence of residual/progressive disease.Funding Information
- Chinese Postdoctoral Science Foundation
This publication has 36 references indexed in Scilit:
- Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines TherapyJournal of Clinical Endocrinology & Metabolism, 2015
- Consensus on biomarkers for neuroendocrine tumour diseaseThe Lancet Oncology, 2015
- The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal TractThe American Journal of Gastroenterology, 2015
- Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease statusEndocrine-Related Cancer, 2015
- A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitorsEndocrine Connections, 2014
- A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detectionEndocrine-Related Cancer, 2014
- Midgut Neuroendocrine Tumors: Imaging Assessment for Surgical ResectionRadioGraphics, 2014
- Combination of Cross-Sectional and Molecular Imaging Studies in the Localization of Gastroenteropancreatic Neuroendocrine TumorsNeuroendocrinology, 2014
- Limitations of Chromogranin A in clinical practiceBiomarkers, 2012
- Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor DiseaseAnnals of Surgical Oncology, 2010